Huynh, C., Dingemanse, J., Meyer zu Schwabedissen, H. E., Fonseca, M., & Sidharta, P. N. (2024). The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239. Clinical and translational science, 17(7), e13883-n/a. https://doi.org/10.1111/cts.13883
Chicago-Zitierstil (17. Ausg.)Huynh, Christine, Jasper Dingemanse, Henriette E. Meyer zu Schwabedissen, Marlene Fonseca, und Patricia N. Sidharta. "The Effect of Itraconazole, a Strong CYP3A4 Inhibitor, on the Pharmacokinetics of the First‐in‐class ACKR3/CXCR7 Antagonist, ACT‐1004‐1239." Clinical and Translational Science 17, no. 7 (2024): e13883-n/a. https://doi.org/10.1111/cts.13883.
MLA-Zitierstil (9. Ausg.)Huynh, Christine, et al. "The Effect of Itraconazole, a Strong CYP3A4 Inhibitor, on the Pharmacokinetics of the First‐in‐class ACKR3/CXCR7 Antagonist, ACT‐1004‐1239." Clinical and Translational Science, vol. 17, no. 7, 2024, pp. e13883-n/a, https://doi.org/10.1111/cts.13883.